Akoya Biosciences (AKYA) Form 3 Akoya Biosciences / J MATTHEW MACKOWSKI ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Raffin Thomas A.

(Last) (First) (Middle)

100 CAMPUS DRIVE, 6TH FLOOR

(Street)

MARLBOROUGH MA 01752

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/20/2021

3. Issuer Name and Ticker or Trading Symbol
Akoya Biosciences, Inc. [ AKYA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	429,184	D
Common Stock	14,134,162	I	See Footnote(1)
Common Stock	1,541,085	I	See Footnote(2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Raffin Thomas A.

(Last) (First) (Middle)

100 CAMPUS DRIVE, 6TH FLOOR

(Street)

MARLBOROUGH MA 01752

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

MACKOWSKI J MATTHEW

(Last) (First) (Middle)

360 POST STREET, SUITE 601

(Street)

SAN FRANCISCO CA 94108

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Lashkari Deval

(Last) (First) (Middle)

360 POST STREET, SUITE 601

(Street)

SAN FRANCISCO CA 94108

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Telegraph Hill Partners III, L.P.

(Last) (First) (Middle)

360 POST STREET, SUITE 601

(Street)

SAN FRANCISCO CA 94108

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

THP III Affiliates Fund, LLC

(Last) (First) (Middle)

360 POST STREET, SUITE 601

(Street)

SAN FRANCISCO CA 94108

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Telegraph Hill Partners III Investment Management, LLC

(Last) (First) (Middle)

360 POST STREET

SUITE 601

(Street)

SAN FRANCISCO CA 94108

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Telegraph Hill Partners Management Company, LLC

(Last) (First) (Middle)

360 POST STREET

SUITE 601

(Street)

SAN FRANCISCO CA 94108

(City) (State) (Zip)

Explanation of Responses:

1. Shares held directly by Telegraph Hill Partners III, L.P. ("THP III"). Telegraph Hill Partners III Investment Management, LLC ("THP IM") is the general partner of THP III. Telegraph Hill Partners Management Company, LLC ("THPMC") is the manager of THP IM. J. Matthew Mackowski, Dr. Thomas A. Raffin and Deval Lashkari are each managers of THPMC and are deemed to have beneficial ownership of the shares held by THP III.

2. Shares held directly by THP III Affiliates Fund, LLC ("THP III AFF"). THP IM is the manager of THP III AFF. THPMC is the manager of THP IM. J. Matthew Mackowski, Dr. Thomas A. Raffin and Deval Lashkari are each managers of THPMC and are deemed to have beneficial ownership of the shares held by THP III Affiliates.

Remarks:

Exhibit 24.1 Power of Attorney. Thomas A. Raffin is a member of the board of directors of Akoya Biosciences, Inc.

	/s/ Thomas A. Raffin, Brian McKelligon, Attorney-in-Fact	04/20/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.